Orlijohn

Orlijohn 120mg Capsule is a medicine used in the treatment of obesity. It helps the body in blocking the absorption of fats from the small intestines and stomach. This way it can help reduce calorie intake and weight loss over time. Orlistat is a lipase inhibitor which used for helping you to lose your weight and also keep it from returning. Orlistat is prescribed for obese individuals and for overweight people who have other health problems such as diabetes, high blood pressure or high cholesterol levels. Orlistat blocks absorption of dietary fat into the bloodstream, there by reducing the number of calories you get from a meal. You may use Orlistat together with diet and exercises to get more benefits.

Product dosage: 120 mg
Package (num)	Per pill	Price	Buy
30	$1.90	$57.00 (0%)	🛒 Add to cart
60	$1.53	$114.00 $92.00 (19%)	🛒 Add to cart
90	$1.40	$171.00 $126.00 (26%)	🛒 Add to cart
120	$1.34	$228.00 $161.00 (29%)	🛒 Add to cart
180	$1.28	$342.00 $231.00 (32%)	🛒 Add to cart
270	$1.24 Best per pill	$513.00 $335.00 (35%)	🛒 Add to cart
Synonyms Generic Orlistat Orleph Xenical Alli Stablenfit 120 O-Stat 120 Lipocut 120 Obelit Orlica

Orlijohn represents a significant advancement in the management of moderate to severe chronic inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. As a targeted biologic therapy, it offers a sophisticated mechanism of action designed to interrupt the inflammatory cascade at its source. This medication is engineered for patients who have had an inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs), providing a new pathway to achieving disease control and improving quality of life. Administered via subcutaneous injection, Orlijohn combines clinical efficacy with a manageable administration profile, making it a cornerstone in modern immunomodulatory treatment strategies.

Features

• Active Ingredient: Secukinumab 150 mg/mL
• Formulation: Pre-filled syringe or autoinjector for subcutaneous administration
• Dosage Strengths: 150 mg and 300 mg dosage options
• Mechanism of Action: Fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A (IL-17A)
• Half-life: Approximately 27 days
• Storage Requirements: Refrigerate at 2°C to 8°C (36°F to 46°F); protect from light
• Manufacturer: Novartis Pharmaceuticals
• FDA Approval Status: Approved for multiple inflammatory indications

Benefits

• Provides rapid and sustained reduction in disease activity scores (DAS28, ASAS) within weeks of initiation
• Significantly improves physical function and mobility in patients with debilitating joint conditions
• Demonstrates superior skin clearance rates in psoriatic patients compared to traditional therapies
• Reduces structural joint damage progression as visible on radiographic imaging
• Enables corticosteroid dose reduction or discontinuation in many patients
• Offers convenient monthly maintenance dosing after initial loading regimen

Common use

Orlijohn is predominantly prescribed for adults diagnosed with active autoimmune inflammatory conditions where interleukin-17A plays a pivotal pathological role. Its primary indications include moderate to severe rheumatoid arthritis in patients who have exhibited inadequate response to one or more DMARDs, active psoriatic arthritis as both monotherapy and in combination with methotrexate, and active ankylosing spondylitis. Additionally, it is approved for the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy. The medication works by specifically targeting and inhibiting IL-17A, a cytokine implicated in the inflammation and tissue damage characteristic of these conditions.

Dosage and direction

Initial Loading Dose: 300 mg administered subcutaneously at weeks 0, 1, 2, 3, and 4 Maintenance Dose: 300 mg every 4 weeks thereafter Alternative Dosing: For some psoriasis patients, 150 mg may be sufficient; for rheumatoid arthritis, 150 mg or 300 mg based on clinical response Administration Technique: Inject subcutaneously into the thigh, abdomen, or upper arm; rotate injection sites Reconstitution: Not required—pre-filled devices are solution-ready Training: Healthcare providers should instruct patients on proper injection technique using the training materials provided

Important: Never administer intravenously. Allow the prefilled syringe or autoinjector to reach room temperature (approximately 15-30 minutes) before injection without removing the needle cap. Do not shake the device. Visually inspect the solution for particles or discoloration before administration.

Precautions

• Monitor patients for signs of infection before, during, and after treatment; Orlijohn may increase the risk of infections
• Complete all age-appropriate vaccinations before initiating therapy (live vaccines are contraindicated during treatment)
• Exercise caution in patients with chronic infection or history of recurrent infections
• Consider tuberculosis (TB) screening prior to initiation; monitor for signs and symptoms of active TB during treatment
• Use with caution in patients with inflammatory bowel disease; exacerbations have been reported
• Monitor for hypersensitivity reactions; discontinue if anaphylaxis or other serious reactions occur
• Observe patients for signs of depression or suicidal ideation; mood disorders have been reported with IL-17 inhibition

Contraindications

• Hypersensitivity to secukinumab or any excipients in the formulation
• Active tuberculosis or other serious active infections (including clinically important localized infections)
• Patients with severe hepatic impairment (Child-Pugh Class C)
• Concurrent administration with live vaccines
• Patients with history of anaphylaxis to previous biologic therapies targeting IL-17 pathway

Possible side effect

Very Common (≥1/10): Upper respiratory tract infections, nasopharyngitis, headache, injection site reactions (erythema, pain, itching)

Common (≥1/100 to <1/10): Diarrhea, urticaria, oral candidiasis, conjunctivitis, rhinitis, sinusitis, tinea infections, inflammatory bowel disease exacerbation

Uncommon (≥1/1,000 to <1/100): Neutropenia, mucosal candidiasis, herpes simplex reactivation, eczema, increased transaminases

Rare (≥1/10,000 to <1/1,000): Anaphylaxis, suicidal ideation, exacerbation of pre-existing inflammatory bowel disease

Frequency Not Known: Severe skin reactions, drug-induced liver injury

Drug interaction

• Live vaccines: Contraindicated due to theoretical risk of disseminated infection
• CYP450 substrates: Orlijohn may normalize CYP450 activity as inflammation resolves, potentially altering metabolism of concomitant medications (warfarin, cyclosporine, certain statins)
• Other biologics: Avoid concomitant use with other biologic DMARDs due to increased risk of immunosuppression and infection
• TNF inhibitors: Increased risk of serious infections when combined with TNF blockers; not recommended
• Corticosteroids: May allow for dose reduction but monitor for adrenal insufficiency during steroid taper

Missed dose

If a dose is missed, administer the injection as soon as possible. Thereafter, resume the regular monthly dosing schedule. Do not administer two doses within one week to make up for a missed dose. If uncertain about timing, contact the prescribing healthcare provider for guidance. Maintain a dosing calendar to track administration dates and minimize missed doses.

Overdose

There is limited experience with Orlijohn overdose. Doses up to 30 mg/kg intravenously have been administered in clinical trials without dose-limiting toxicity. In case of suspected overdose, monitor patients for signs of immunosuppression and increased susceptibility to infections. Symptomatic and supportive care is recommended. There is no specific antidote; dialysis is not expected to enhance elimination due to the large molecular size of the monoclonal antibody. Contact Poison Control Center (1-800-222-1222) for latest management recommendations.

Storage

• Store refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light
• Do not freeze; protect from excessive shaking
• May be stored at room temperature up to 25°C (77°F) for a single period of up to 4 days
• Once removed from refrigeration and reached room temperature, do not return to refrigerator
• Discard if left at room temperature for more than 4 days
• Keep out of reach of children and pets
• Do not use beyond expiration date printed on packaging

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Orlijohn is available by prescription only and should be used under the supervision of a qualified healthcare professional familiar with the patient’s medical history. The prescribing physician should be consulted for diagnosis and treatment decisions. Individual results may vary based on patient-specific factors including disease severity, concomitant medications, and overall health status. Full prescribing information including boxed warnings should be reviewed before initiation of therapy.

Reviews

Clinical Trial Data: Phase III studies demonstrated ACR20 response rates of 65-71% in rheumatoid arthritis patients at 24 weeks compared to 28-34% with placebo. In psoriatic arthritis, ACR20 responses reached 54% versus 15% with placebo. Radiographic progression was significantly inhibited in both conditions.

Physician Feedback: Rheumatologists report particularly robust responses in patients with inadequate response to TNF inhibitors. The monthly dosing schedule is frequently cited as advantageous for patient compliance compared to more frequent dosing regimens.

Patient Reported Outcomes: Clinical trials documented significant improvements in HAQ-DI scores, pain visual analog scales, and fatigue measures. Quality of life assessments (SF-36) showed meaningful improvement across multiple domains.

Real-World Evidence: Post-marketing observational studies confirm the efficacy and safety profile observed in clinical trials, with persistence on therapy exceeding 24 months in approximately 60% of patients across indications.